COMP <GO>
AORT vs ABBV // NET PROFIT MARGIN
Artivion Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: AORT 4
— ABBV 9
▲ NET PROFIT MARGIN LEADER: ABBV
LAST: $23.44 (+2.27%) • MKT CAP: $1.14B
net-margins
2.20%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
net-margins
6.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AORT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AORT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.40% | 70.20% | -5.80 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.50% | 29.00% | -24.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.3x | 33.3x | -14.00 | AORT | /valuation <GO> |
| Free Cash Flow Yield | 0.07% | 3.47% | -3.40 | ABBV | /fcf-yield <GO> |
| Operating Margin | 7.60% | 24.60% | -17.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 2.20% | 6.90% | -4.70 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 13.60% | 8.60% | +5.00 | AORT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.46 | 5.33 | -2.87 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | AORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.6 | 65.1 | -11.50 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 98.3x | 113.1x | -14.80 | AORT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.14B | $513.86B | -$512.72B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AORT REV | ABBV REV | AORT GROSS % | ABBV GROSS % | AORT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $441.3M | $61.16B | 64.4% | 70.2% | $839.0K | $17.82B |
| FY 2024 | $388.5M | $56.33B | 64.0% | 70.0% | $11.0M | $17.83B |
| FY 2023 | $354.0M | $54.32B | — | — | $18.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AORT // BETA —
ABBV // BETA 1.15